Drug Trial Radar · NCT05899608
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,600
Planned (sponsor's estimate)
Start
Oct 26, 2023
Primary completion
Dec 31, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Summit TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.
Conditions
- Non-Small Cell Lung Cancer
Interventions
Ivonescimab InjectionBiological
Subject will receive ivonescimab and chemotherapy as an IV injection
Pembrolizumab InjectionBiological
Subject will receive pembrolizumab and chemotherapy as an IV injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: approximately 4 years
- Progression Free Survival (PFS)Time frame: approximately 3 years
Locations
260 sites in 17 countries. Site status is shown where the registry gives one.
Banner University Medical Center
Phoenix, Arizona
TMC Healthcare
Tucson, Arizona
Genesis Cancer and Blood Institute
Hot Springs, Arkansas
University of Arkansas
Little Rock, Arkansas
LA Cancer Network
Anaheim, California
The Oncology Institute of Hope & Innovation
Cerritos, California
University of Southern California (USC)
Los Angeles, California
Cedar Sinai Medical Center
Los Angeles, California
Valkyrie Clinical Trials
Los Angeles, California
Sutter Institute for Medical Research
Sacramento, California
UC Davis Medical Center
Sacramento, California
University of California Los Angeles (UCLA)
Santa Monica, California
Providence Medical Foundation
Santa Rosa, California
Kaiser Permanente
Vallejo, California
Rocky Mountain Cancer
Lone Tree, Colorado
Banner MD Anderson Cancer Center at North Colorado Medical Center
Loveland, Colorado
Hartford Hospital
Hartford, Connecticut
Yale University
New Haven, Connecticut
Florida Cancer Specialists & Research Institute (FCS)-East
Fort Myers, Florida
BioResearch Partner- Hialeah Hospital
Hialeah, Florida
Memorial Healthcare System
Hollywood, Florida
Mayo Clinic
Jacksonville, Florida
Cancer Specialists of North Florida
Jacksonville, Florida
Ocala Oncology
Ocala, Florida
Cancer Care of Brevard
Palm Bay, Florida
Ascension Sacred Heart Health System
Pensacola, Florida
Exigent Network
Petersburg, Florida
BRCR Medical Center Inc
Plantation, Florida
Florida Cancer Specialists & Research Institute (FCS) - North
St. Petersburg, Florida
BRCR Medical Center Inc.
Tamarac, Florida
Florida Cancer Specialists & Research Institute (FCS)-South
West Palm Beach, Florida
Central Georgia Cancer Care
Macon, Georgia
Northwestern Memorial Hospital
Chicago, Illinois
Illinois Cancer Care P.C.
Peoria, Illinois
University of Kansas Cancer Center
Westwood, Kansas
Baptist Health
Lexington, Kentucky
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Ascension Saint Agnes Hospital
Baltimore, Maryland
Lahey Hospital
Burlington, Massachusetts
University of Michigan
Ann Arbor, Michigan
Showing 40 of 260 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.